ArticleJournal of molecular histology2026
Sunflower oil-loaded lycopene protects intestinal barrier integrity following traumatic brain injury.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Traumatic brain injury (TBI) is a major cause of morbidity, mortality, and long-term neurological impairment. Growing evidence suggests that the gut-brain axis plays a crucial role in TBI pathophysiology, with gut microbiota dysbiosis potentially inducing inflammation and aggravating brain injury. Lycopene (Lyc), a potent antioxidant derived from tomatoes with neuroprotective and anti-inflammatory properties, is considered a promising potential therapy for TBI. Sunflower oil (SO) can effectively enhance Lyc bioavailability. We established a TBI mouse model and treated it with SO-loaded Lyc (SO-Lyc). Serum and fecal samples were collected for metabolomic analysis, 16S rRNA sequencing for gut microbiota changes, ELISA for inflammatory cytokines and injury markers, H&E staining for gut/brain histopathology, and immunohistochemistry for intestinal barrier-related gene expression. Furthermore, we used 16S rRNA data from patient samples with TBI to perform association analyses. The results showed that SO-Lyc supplementation may mitigate damage to intestinal and cerebral tissues by restoring intestinal barrier function and suppressing systemic inflammation through modulation of key metabolic pathways, such as those involving linoleic acid, sphingolipids, and tryptophan. Its effects manifest as reduced serum inflammatory cytokines (TNF-α, IL-6, CRP, IL-1β), intestinal injury markers (DAO, D-LA, I-FABP, ET), and brain injury markers (NFL, GFAP, S100B, NSE, UCH-L1), while enhancing the expression of intestinal barrier genes (occludin and ZO-1). Furthermore, this supplement promotes the growth of gut microbiota with anti-inflammatory properties. Differences in inflammation and gut microbiota have been observed among TBI patients with varying degrees of severity, suggesting that Lyc containing SO may be an effective treatment for TBI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.